Max Salm
35 works · 6,035 citations · h-index 12
Top works
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
- Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
- Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
- Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer
- CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients
- Deciphering clonality in aneuploid tumors using SNP array and sequencing data
- A modular protein language modelling approach to immunogenicity prediction
- Breaking the performance ceiling for neoantigen immunogenicity prediction
- pdxBlacklist: Identifying artefactual variants in patient-derived xenograft samples
- Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs.
- 114 Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma
- Evolution of the Genomic Landscape in Non-Small Cell Lung Cancer
- Towards industry 4.0: development of a smart bioprocessing platform integrating real-time monitoring and advanced process control for autologous cell therapy
- Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction
- Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use